Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Leukemia|April 28, 2018
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatmentsPaolo Ghia, Andy RawstronBest Practice & Research. Clinical Haematology|July 13, 2010
Is MRD eradication a desirable goal in CLL?Carol Moreno, Matthias Ritgen, Andy RawstronSeminars in Hematology|July 23, 2004
Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patientsAndy Rawstron, Peter Hillmen, Richard HoulstonBritish Journal of Haematology|October 4, 2007
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 studySylvia Feyler, Andy Rawstron, Graham Jackson, et al.Blood|March 6, 2002
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemiaBen Kennedy, Andy Rawstron, Chris Carter, et al.British Journal of Haematology|November 6, 2007
B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycleFiona Bennett, Andy Rawstron, Marieth Plummer, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 12, 2017
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell TransitionGururaj Arumugakani, Sophie J Stephenson, Darren J Newton, et al.Haematologica|March 20, 2025
Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK's Haematological Malignancy Research NetworkAlexandra Smith, Timothy Bagguley, Eve Roman, et al.British Journal of Haematology|January 13, 2009
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burdenSylvia Feyler, Marie von Lilienfeld-Toal, Sarah Jarmin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalPaul Moreton, Ben Kennedy, Guy Lucas, et al.Pageof 3